Investigating how Urotensin II affects kidney function in growth-restricted infants.
Urotensin II and renal insufficiency in growth-restricted infants.
['FUNDING_R01'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-10908605
This study is looking at how a substance called Urotensin II might affect the kidneys of babies who didn't grow as much as expected before birth, with the hope of finding ways to help these little ones stay healthier.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-10908605 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of Urotensin II (UII), a peptide that influences kidney function, in infants who have experienced intrauterine growth restriction (IUGR). The study aims to explore how increased levels of UII may contribute to kidney injury in these newborns. By using a preclinical model of growth-restricted pigs, researchers will examine the mechanisms through which UII affects renal function and overall health. The goal is to identify potential interventions that could improve outcomes for affected infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are newborns who are diagnosed with intrauterine growth restriction.
Not a fit: Patients who are not newborns or do not have a history of intrauterine growth restriction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for kidney issues in growth-restricted infants, potentially reducing long-term health complications.
How similar studies have performed: Previous research has shown that understanding the role of vasoactive peptides like Urotensin II can lead to significant insights into kidney function, suggesting potential for success in this novel approach.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ADEBIYI, ADEBOWALE — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: ADEBIYI, ADEBOWALE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bright Disease, Cardiac Diseases